Pharmacogenomics (PGx)

Finding an optimal medication for patients diagnosed with a mental illness has traditionally relied on trial and error, resulting in inadequate therapy response, low remission rates and a high rate of adverse drug events. Using current standard-of-care treatment approaches, less than half of patients with major depressive disorder achieve an adequate response to first line treatment, and nearly three out of four do not achieve remission. There is a high prevalence of adverse drug events and increasing rates of discontinuation with repeated medication trials. This frustration has led to a need in the mental health community for more personalized care with the selection of an optimal therapy the first time, achieving a fast response/remission with few-to-no side effects and at a low out-of-pocket cost.

For the 50 million patients experiencing mental health illness in the United States, meeting these expectations will require a new approach to medication selection. Pharmacogenomic testing (PGx) can improve medication selection and avoid the need for multiple medication trials. Traditional PGx tests are designed to assess a patient’s DNA to identify variances that result in drug-gene interactions. These interactions can lead to a variation in medication responses by altering drug metabolism or impacting how the body responds to a drug. In addition to drug-gene interactions, our IDgenetix test incorporates drug-drug interactions and lifestyle factors into the final patient report, which we believe offers additional value to clinicians and patients.

A person flips open a pill box to take their daily medication
Click to learn more
Next section

Castle Laboratories

View More